Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 23;40:205. doi: 10.1186/s13046-021-02015-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — LncRNA CARMN decreases with malignant change of breast tissue and predicts prognosis in breast cancer. A Venn diagram for screening lncRNAs differently expressed in breast cancer from normal breast tissue in TCGA database, GSE45827, GSE31192, GSE3744 and GSE21422, respectively. LncRNA CARMN is decreased in tumor tissue in all 5 databases. B CARMN expression in paired breast cancer and normal breast tissue in TCGA database and distribution of changing tendency. C Expression of CARMN detected by RT-qPCR in paired breast cancer and normal breast tissue from Renji cohort. D Expression of CARMN in different clinical stages of breast cancer in TCGA. E CARMN expression in paired hyperplastic enlarged lobular units (HELU) and terminal duct lobular units (TDLU) in GSE7377. F CARMN expression in normal breast tissue, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) in GSE21422. G Expression of CARMN in different subtypes of breast cancer according to GSE45827. H Comparison of CARMN expression in TNBC and non-TNBC according to TCGA dataset. I Relapse-free survival (RFS) of all breast cancer patients with different expression of CARMN according to Kaplan-Meier Plotter. J Overall survival (OS) of all breast cancer patients with different CARMN expression according to Kaplan-Meier Plotter. K Disease-free survival (DFS) of patients with different expression of CARMN who received neoadjuvant chemotherapy in Renji cohort. L Recurrence-free survival (RFS) of TNBC patients with different expression of CARMN according to Kaplan-Meier Plotter. T: tumor; N: normal; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple negative breast cancer; HELU: hyperplastic enlarged lobular units; TDLU: terminal duct lobular units; RFS:Relapse-free survival; OS: Overall survival; DFS, Disease-free survival. Error bars represent means ± SD, *P < 0.05, **P < 0.01, ***P < 0.001